WallStSmart
NGNE

Neurogene Inc

NASDAQ: NGNE · HEALTHCARE · BIOTECHNOLOGY

$31.54
-3.60% today

Updated 2026-06-05

Market cap
$418.59M
P/E ratio
P/S ratio
438.73x
EPS (TTM)
$-4.55
Dividend yield
52W range
$15 – $37
Volume
0.1M

Neurogene Inc (NGNE) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item201120122013201420152016201720182019202020212022202320242025
Total assets$9.88M$2.34M$58.77M$41.42M$113.34M$154.38M$110.33M$77.62M$147.02M$210.52M$101.49M$109.27M$222.57M$335.73M$288.60M
Cash & equivalents$9.24M$2.00M$54.13M$14.91M$39.53M$32.30M$52.03M$76.93M$143.09M$192.56M$70.54M$82.02M$148.21M$136.59M$103.84M
Current assets$9.49M$2.06M$57.04M$39.30M$74.80M$103.48M$108.83M$77.17M$143.60M$194.52M$73.96M$84.72M$200.35M$315.92M$271.77M
Total liabilities$1.30M$1.47M$7.48M$5.28M$4.92M$9.72M$11.44M$4.95M$5.34M$19.30M$193.36M$10.64M$36.55M$25.36M$23.72M
Current liabilities$607889.00$385387.00$2.62M$5.20M$4.79M$9.52M$10.96M$4.63M$4.74M$7.89M$10.86M$6.65M$22.97M$15.16M$16.41M
Long-term debt
Shareholder equity$8.59M$874030.00$51.28M$36.15M$108.42M$144.66M$98.89M$72.67M$141.69M$191.22M$-91.88M$98.63M$186.02M$310.38M$264.89M
Retained earnings$-39.85M$-51.64M$-63.63M$-89.42M$-111.28M$-148.28M$-198.50M$-230.09M$-299.53M$-332.81M$-95.65M$-150.84M$-187.15M$-262.30M$-352.65M
Accounts receivable$219550.00$28545.00$27946.00$65447.00$31999.00$790000.00$990000.00$600000.00$648000.00
Inventory$1.91M$1.08M$1.50M
Goodwill

Frequently asked questions

How much free cash flow does NGNE generate?

NGNE produced $-78.36M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is NGNE's balance sheet healthy?

NGNE holds $103.84M in cash and equivalents against — in long-term debt, on $264.89M of shareholder equity. That debt is best read against the cash flow the business throws off each year.